Ranbaxy-AstraZeneca Pact Part Of Indian Drug Maker Trend
This article was originally published in PharmAsia News
Executive Summary
The patent-dispute settlement Ranbaxy Pharmaceuticals reached with AstraZeneca reflects a new Indian trend beyond the business of making generics. The settlement terms include Ranbaxy selling AstraZeneca's Nexium (esomeprazole) when the first of several patents expires in 2014. Like other Indian drug makers, Ranbaxy is expanding beyond the generics market to improve its research and development capabilities and make a dent in the branded drugs market. Ranbaxy plans to split its generics and branded efforts this summer, a move being taken by several Indian competitors with similar plans. (Click here for more